Want Reliable Dividend Passive Income? These 5 Stocks Raise Their Payouts Year After Year24/7 Wall Street • 2h
Johnson & Johnson data in psoriatic arthritis (PsA) shows TREMFYA (guselkumab) is the only advanced therapy to demonstrate MRI-confirmed improvements in spinal pain and stiffnessPRNewsWire • 2h
Johnson & Johnson Delivered 'Immaculate' Prostate Cancer Data at ESMO. Here's Why Investors Should CareThe Motley Fool • Thursday
3 Dow Dividend Passive Income Stocks for Retirement, Led by a 64-Year Streak24/7 Wall Street • Thursday
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJPRNewsWire • Thursday
Johnson & Johnson Announces First Commercial Installation of the OTTAVA™ Robotic Surgical System at Memorial Hermann Health SystemBusiness Wire • Thursday
Want Steady Dividend Income? Invest in These 3 Dividend Kings With 64 Years of Raises24/7 Wall Street • Thursday
Want Reliable Retirement Income? Invest in These 3 Dow Jones Passive Income Dividend Stocks24/7 Wall Street • Thursday
Johnson & Johnson Seeks U.S. FDA Approval for CAPLYTA in Bipolar Mania, Marking Fifth Potential IndicationPRNewsWire • Thursday
Invest $25,000 in These 4 Dividend Stocks to Start Building Retirement Income24/7 Wall Street • Wednesday
Here's How Much Passive Income $50,000 Generates in These 4 Dividend Aristocrats24/7 Wall Street • Wednesday
Johnson & Johnson vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?The Motley Fool • Tuesday
Louisiana Appeals Court Upholds Millions in Damages in Mesothelioma Case Against Johnson & JohnsonBusiness Wire • Tuesday
Wall Street Analysts Think Johnson & Johnson (JNJ) Is a Good Investment: Is It?Zacks Investment Research • Tuesday
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending StockZacks Investment Research • Tuesday
J&J Stock Rallies More Than 10% in a Month: Time to Buy, Sell or Hold?Zacks Investment Research • Monday
Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmologyBusiness Wire • Monday